For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help lifesaving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory, and therapeutic expertise, our team of more than 21,000 global professionals works in partnership with biopharmaceutical leaders, emerging innovators, and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere.
Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers quality solutions to make every phase of the clinical trial process more efficient. Our top-notch people, insight, and focus on operational excellence allow us to work every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference.
This approach continues to earn us recognition industrywide, with Parexel being named “Best Contract Research Organization” in November 2023 by an independent panel for Citeline, “Top CRO to Work With” by investigative sites worldwide in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey and recipient of the 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships.
Within clinical research, patient diversity is critical. Inclusive studies move us closer to healthcare equity and more accurately reflect real-world populations — resulting in a far greater understanding of how the treatment will affect the people who need it. Our approach to designing more diverse, accessible trials is leading the industry forward.
Our family of brands
Your trusted partner in learning. Parexel Academy is committed to building and enhancing capabilities within the clinical research workforce so that, together, we make a positive impact on the lives of patients around the world.
Each of us, no matter what we do at Parexel, contributes to the development of a therapy that ultimately will benefit a patient. We take our work personally, we do it with empathy, and we're committed to making a difference.
From the smallest detail to the largest, we take quality seriously. We focus on the details while never losing sight of the big picture to drive the best possible outcome.
In our quest for innovation, we recognize and uphold the importance of all people, from our employees to our clients and the patients we all serve.
We follow our hearts, we do the right thing, and we have the courage to own the outcome.
Awards & Recognition
Parexel was named “Best Contract Research Organization” in the Full-Service Provider category at the 19th Annual Scrip Awards. The annual Scrip Awards, organized by Citeline, are designed to celebrate and recognize the very best innovations and achievements in global biopharma.
Parexel was recognized with the 2023 Healthcare Businesswomen’s Association’s (HBA) “Advancement. Commitment. Engagement (ACE) Award,” which recognizes companies for their creation and implementation of initiatives that deliver impactful outcomes designed to close the gender gap in the healthcare ecosystem. Parexel was one of two companies chosen as a result of the strong outcomes from its business initiative “Priority: Advancing Women in Leadership.”
The SCRS Eagle Award recognizes the sponsor and CRO committed to outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships. Recipients of the Eagle Award are selected based on votes cast from the global site community.
For the second year in a row, Parexel has received a “silver” rating in the 2023 EcoVadis Sustainability Rating Program. Ecovadis is the world’s largest and most trusted provider of business sustainability ratings. A silver rating is awarded to organizations with a structured and proactive sustainability approach with strong reporting on KPIs and actions.
Parexel has been recognized with CRO Leadership Awards for the 12th consecutive year across all five categories – Capabilities, Compatibility, Expertise, Quality, and Reliability – for exceeding customer expectations in different customer segments. Winning CROs are chosen based on feedback from sponsor companies that they have worked on an outsourced project within the previous 18 months.
Parexel was ranked as the “Top CRO to Work With” by investigative sites worldwide in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey for the second straight time. Among 34 CROs, Parexel received the highest average rating across all 26 performance attributes evaluated in the survey. In addition to receiving the highest average rating across all attributes, Parexel ranked highest on four out of the five attributes considered the most important to investigative sites and was selected as the CRO that investigative sites were most willing to recommend to a colleague.
Parexel was named a 2022 Catalyst Award winner by the global nonprofit organization Catalyst. Parexel was recognized for its Leveraging Gender Partnership to Advance Women in Leadership initiative that has evolved the company culture to one where women have the right resources and training to succeed.
Parexel was recognized as a company to watch on FlexJobs' 10th annual list of the Top 100 Companies to Watch for Remote Jobs in 2023. Parexel is one of only five companies to have made the FlexJobs' list each year since its inception in 2014.
Parexel is proud to be featured on the Human Rights Campaign’s 2022 Corporate Equality Index, the premier survey benchmarking tool on how corporations across the US and beyond are adopting equitable workplace policies, practices and benefits for LGBTQ+ employees